300+ investors in your industry, stage, and region Get
Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Burkina Faso
LATAM
Brazil
Africa
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Sweden
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Oman
Poland
Puerto Rico
Guernsey
Cameroon
Colombia
China
Armenia
Costa Rica
Czech Republic
Marshall Islands
Kuwait
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Morocco
Moldova
Paraguay
Seychelles
Botswana
South Africa
France
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Angola
Europe
Cyprus
Spain
Qatar
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
BNH Investment, VC Fund

BNH Investment

VC Fund

Seoul, South Korea

BNH Investment is an investment company for bio and healthcare sectors.

Total investments:
43
Last investment:
Lead investor:
9%

Last updated:

Industries BNH Investment invests in

BiotechnologyPharmaceuticalMedicalHealth CareSoftware

Stages BNH Investment invests in

Series BSeries ASeries CVenture - Series UnknownFunding Round

Countries BNH Investment invests in

South Korea

Round sizes

Series A $2.2M–$11MSeries B $7.3M–$20MSeries C $8.2M–$23M

Round size

Series A
$2.2M–$11M
Series B
$7.3M–$20M
Series C
$8.2M–$23M

Investment Focus

Industry

  • Biotechnology 21 (49%)
  • Pharmaceutical 10 (23%)
  • Medical 8 (19%)
  • Health Care 8 (19%)
  • Software 5 (12%)
See all 36 industries →

Stage

  • Series B 11 (26%)
  • Series A 10 (23%)
  • Series C 7 (16%)
  • Venture - Series Unknown 7 (16%)
  • Funding Round 3 (7%)
See all 8 stages →

Investments

CompanyDescriptionRoundLinks
LabInCube develops inCube materials capable of selective drug release, sustained release, and supporting complex raw materials. $9.8M / Series B / Mar 18, 2026
MustBio is a biotechnology company that leverages multi-antibody technology to develop therapeutics primarily in the field of immuno-oncology. The company was founded in 2021 and is based in Seoul, South Korea. $23.3M / Series C / Mar 13, 2026
ENCell is a biotech company that develops and manufactures biopharmaceuticals. $15.3M / Post-IPO Debt / Dec 04, 2025
Portrai is a biotechnology research company utilizing AI in spatial transcriptomics to improve biopsy quality. The company specializes in developing highly accurate artificial intelligence technology to analyze spatial transcriptomics results. This enables doctors to efficiently examine a patient's illness by analyzing tissue samples withprecision. $9.9M / Series B / Dec 02, 2025
Plcoskin is a MedTech company specializing in reconstructive plastic surgery and regenerative skincare. They have developed a scaffold that removes the need for cadaver-sourced material used in breast reconstruction surgery, making procedures safer and cheaper. Plcoskin’s scaffolds are made with synthetic PCL, a biodegradable material that iscommonly used to create surgical sutures. Unlike competitors' products that remain in the body for a lifetime, Plcoskin’s PCL scaffolds are absorbed and replaced with the recipient’s own natural tissues, minimizing the possibility of long-term side effects. As they do not contain any dangerous chemicals, they are also 50% safer than cadaver-sourced scaffolds.Costs for reconstructive breast surgery are brought down by 40% to only $3 thousand per breast. Furthermore, much less handling time is required, reducing average surgery durations from an hour and a half to only 30 minutes. The mesh design of the scaffolds mitigates the need for an additional follow-up reconstructive surgery, something that is common when using cadaver-sourced scaffolds.Plcoskin has also developed Youlief, a cosmeceutical product & therapeutic device pipeline that helps fund R&D for their medical devices. Youlief is available in the US, Europe, Taiwan, Singapore and Japan. $10.1M / Series C / Oct 27, 2025
Pinot Bio is a biotechnology company that specializes in developing new generation anticancer treatments. $9.1M / Oct 27, 2025
MediMabBio platform uses systems biology combined with sophisticated immunological solutions to identify significantly improving immuno-oncology drugs that can actively target a range of solid tumors. The antibody discovery I-O platform brings the advantages of rational drug design to large molecule therapeutic development. $17.8M / Series B / Oct 24, 2025
Oncosoft develops software solutions with a focus on anti-cancer treatment. Their offerings include an Oncology Information Management Solution (OIMS) and artificial intelligence-based technologies for radiologists. The software aids in the detection of cancer, contributing to the medical community efforts in precision cancer therapy. $8.2M / Series B / Sep 23, 2024
Bazbiomedic is a global innovation company, manufacturer of drug delivery devices intended to improve the healthcare system. Bazbiomedic a needle-free drug delivery device capable of controlling injection depth and volume. $7.3M / Series B / May 10, 2024
LabInCube develops inCube materials capable of selective drug release, sustained release, and supporting complex raw materials. $3.8M / Series A / Apr 02, 2024
See all 43 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Burkina Faso
LATAM
Brazil
Africa
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Sweden
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Oman
Poland
Puerto Rico
Guernsey
Cameroon
Colombia
China
Armenia
Costa Rica
Czech Republic
Marshall Islands
Kuwait
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Morocco
Moldova
Paraguay
Seychelles
Botswana
South Africa
France
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Angola
Europe
Cyprus
Spain
Qatar
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does BNH Investment invest in?

BNH Investment invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Series B and Series A stage. Most of the 43 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What round sizes does BNH Investment invest in?

BNH Investment typically joins rounds of $2.2M–$11M at Series A, $7.3M–$20M at Series B and $8.2M–$23M at Series C. These are whole funding-round sizes, not BNH Investment's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds BNH Investment took part in.

When did BNH Investment last invest?

The most recent investment recorded for BNH Investment closed in Mar 2026. Shizune tracks 43 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
BNH Investment BNH Investment Find emails